Acorda Falls 37% After Five Deaths Stop Enrollment In Parkinson's Study
November 15, 2017 at 10:25 AM EST
Shares of Acorda Therapeutics are sinking after the company announced this morning that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson's disease.
